David Brower

David Brower joined Accent in September 2018 and serves as a Chief Business Officer. David has held a number of life science business development, strategy, and investing roles prior to joining Accent. Most recently, David led the business development function for Blueprint Medicines, where he completed a variety of strategic transactions, including its seminal partnerships with Roche Pharmaceuticals, CStone Pharmaceuticals and Alexion Pharmaceuticals. Prior to Blueprint Medicines, David was a member of Pfizer Pharmaceuticals’ Worldwide Business Development team, focusing on licensing and M&A transactions, and business development strategy. He was previously a healthcare trader and investor for Lehman Brothers and Barclays Capital. David received his M.B.A. with a concentration in healthcare from the Wharton School of Business at the University of Pennsylvania, and his B.A. in biology from Dartmouth College.